Physician profile
Danielle E Mcdonough
NPI 1770954836
$5,099.70
in general payments reported to CMS, 2019-2025
25 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $1,168 · 2023: $1,332 · 2024: $1,310 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,674 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,673.82 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $887.90 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $587.05 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $583.33 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $408.01 | 2022-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $380.29 | 2022-2025 | Verquvo, Januvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.21 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $257.89 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.12 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $224.72 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $155.48 | 2023-2024 | Inpefa |
| Abbott Laboratories | $144.61 | 2021 | |
| Amarin Pharma, INC. | $140.78 | 2022-2023 | |
| Cvrx, INC. | $113.45 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $111.36 | 2022-2025 | Hawkone |
| Novo Nordisk INC | $107.59 | 2023-2025 | Wegovy, Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $105.50 | 2023-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $104.07 | 2022-2023 | |
| Pfizer INC. | $63.53 | 2022-2025 | |
| Boston Scientific Corporation | $59.52 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| Abiomed | $56.13 | 2025 | |
| Inspire Medical Systems, INC. | $24.08 | 2025 | Inspire |
| Scpharmaceuticals INC. | $21.98 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $21.57 | 2022 | |
| Resmed Corp | $21.05 | 2024 | |
| Mimedx Group, INC. | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.